Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

2articles mentioning drugs

23drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: BAL0891 ×

BAL0891

This drug is selected. Its supporting articles are shown below.

Articles mentioning BAL0891

2 articles · page 1 of 1

621 Optimizing immunomodulation of BAL0891, a TTK/PLK1 dual Inhibitor, to enhance synergy with immune checkpoint blockade using a biomimetic tumor microenvironment platform and pharmacometric modeling

jitc · abstract · 2025-11-04 · 13 matching annotations

99.3%

BAL0891 pembrolizumab Cancer Research 2025 NCT05768932 triple-negative breast cancer

…ttps://doi.org/10.1016/j.annonc.2022.01.051Kang M, Yoo S, Ma S. BAL0891 as a dual kinase inhibitor inducing anti-tumor immunity: A prom…

580 Phase 1 study of mitotic checkpoint inhibitor BAL0891 in combination with tislelizumab (anti-PD-1 antibody) in patients with advanced solid tumors

jitc · abstract · 2025-11-04 · 10 matching annotations

99.2%

BAL0891 tislelizumab TTK-CS-101 paclitaxel TTK-CS-001 triple-negative breast cancer

… tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BAL0891 monotherapy and combination with paclitaxel.Trial Registration …